PD-L1 and intratumoral immune response in breast cancer.
PD-L1 and intratumoral immune response in breast cancer.
复制标题
DOI：
10.18632/oncotarget.18305
复制
发表时间：
2017-08-01
期刊：
影响因子：
--
通讯作者：
Watson PH
中科院分区：
文献类型：
--
作者：
Wang ZQ;Milne K;Derocher H;Webb JR;Nelson BH;Watson PH
PD-L1被认为在抗肿瘤免疫应答中发挥重要作用。在这项研究中，我们研究了PD-L1在乳腺肿瘤亚群中的表达，以更好地确定其预后意义。进行免疫组织化学以确定PD-L1肿瘤细胞表达，并在按分子亚型分类的443例乳腺癌队列中计数CD 8、CD 4和CD 68肿瘤浸润性白细胞（TIL）。在整个队列中，在73/443（16.5%）例病例中观察到PD-L1肿瘤细胞表达，并与已知的不良预后指标相关，包括患者年龄低、肿瘤分级高、ER/PR阴性状态，但与结局无关。然而，在三阴性乳腺癌亚组中，PD-L1与更好的无复发生存期（RFS）相关，尤其是在基底样亚组中（风险比= 0.39，95% CI = 0.22 - 0.86，p = 0.018）。在基底细胞样亚组中，PD-L1/上皮CD 8阳性状态与RFS和OS较好也密切相关（分别为风险比= 0.12，95% CI = 0.10 - 0.71，p = 0.010和风险比= 0.11，95% CI = 0.11 - 0.68，p = 0.006）。PD-L1表达与基底细胞样乳腺癌患者更好的生存期相关。
PD-L1 is thought to play an important role in the antitumor immune response. In this study, we investigated the expression of PD-L1 within breast tumor subsets to better define its prognostic significance. Immunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype. Across the entire cohort, PD-L1 tumor cell expression was observed in 73/443 (16.5%) cases and associated with known indicators of poor prognosis, including low patient age, high tumor grade, ER/PR negative status, but not with outcome. However, in the Triple Negative breast cancer subset PD-L1 was associated with better recurrence free survival (RFS) especially within the Basal-like subset (Hazard ratio = 0.39, 95% CI = 0.22 - 0.86, p = 0.018). Combined PD-L1/epithelial CD8 positive status was also strongly associated with better RFS and OS (Hazard ratio = 0.12, 95% CI = 0.10 - 0.71, p = 0.010 and Hazard ratio = 0.11, 95% CI = 0.11 - 0.68, p = 0.006 respectively) in the Basal-like subgroup. PD-L1 expression is associated with better patient survival in Basal-like breast cancer.